Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent
(Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients
with biochemical recurrence after prostatectomy and radiation therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Thomas Hope University of California, San Francisco